Silencing ZEB2 Induces Apoptosis and Reduces Viability in Glioblastoma Cell Lines

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2021 Feb 12

PMID 33572092

Citations 3

Authors

Sahar Safaee

Masoumeh Fardi

Nima Hemmat

Neda Khosravi

Afshin Derakhshani

Nicola Silvestris

Behzad Baradaran

Affiliations

Soon will be listed here.

Abstract

Background: Glioma is an aggressive type of brain tumor that originated from neuroglia cells, accounts for about 80% of all malignant brain tumors. Glioma aggressiveness has been associated with extreme cell proliferation, invasion of malignant cells, and resistance to chemotherapies. Due to resistance to common therapies, glioma affected patients' survival has not been remarkably improved. ZEB2 (SIP1) is a critical transcriptional regulator with various functions during embryonic development and wound healing that has abnormal expression in different malignancies, including brain tumors. ZEB2 overexpression in brain tumors is attributed to an unfavorable state of the malignancy. Therefore, we aimed to investigate some functions of ZEB2 in two different glioblastoma U87 and U373 cell lines.

Methods: In this study, we investigated the effect of ZEB2 knocking down on the apoptosis, cell cycle, cytotoxicity, scratch test of the two malignant brain tumor cell lines U87 and U373. Besides, we investigated possible proteins and microRNA, SMAD2, SMAD5, and miR-214, which interact with ZEB2 via in situ analysis. Then we evaluated candidate gene expression after ZEB2-specific knocking down.

Results: We found that ZEB2 suppression induced apoptosis in U87 and U373 cell lines. Besides, it had cytotoxic effects on both cell lines and reduced cell migration. Cell cycle analysis showed cell cycle arrest in G0/G1 and apoptosis induction in U87 and U373 cell lines receptively. Also, we have found that SAMAD2/5 expression was reduced after ZEB2-siRNA transfection and miR-214 upregulated after transfection.

Conclusions: In line with previous investigations, our results indicated a critical oncogenic role for ZEB2 overexpression in brain glioma tumors. These properties make ZEB2 an essential molecule for further studies in the treatment of glioma cancer.

Citing Articles

In Vitro and Computational Studies of Perezone and Perezone Angelate as Potential Anti-Glioblastoma Multiforme Agents.

Hernandez-Rodriguez M, Mendoza Sanchez P, Martinez J, Macias Perez M, Rosales Cruz E, Zolek T Molecules. 2022; 27(5).

PMID: 35268667 PMC: 8911992. DOI: 10.3390/molecules27051565.

The Bright and the Dark Side of TGF-β Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications.

Gungor M, Uysal M, Senturk S Cancers (Basel). 2022; 14(4).

PMID: 35205692 PMC: 8870127. DOI: 10.3390/cancers14040940.

EphrinB2-EphB4 Signaling in Neurooncological Disease.

Piffko A, Uhl C, Vajkoczy P, Czabanka M, Broggini T Int J Mol Sci. 2022; 23(3).

PMID: 35163601 PMC: 8836162. DOI: 10.3390/ijms23031679.

References

Yue S, Wang L, Zhang H, Min Y, Lou Y, Sun H . miR-139-5p suppresses cancer cell migration and invasion through targeting ZEB1 and ZEB2 in GBM. Tumour Biol. 2015; 36(9):6741-9. DOI: 10.1007/s13277-015-3372-8. View

Pang H, Zheng Y, Zhao Y, Xiu X, Wang J . miR-590-3p suppresses cancer cell migration, invasion and epithelial-mesenchymal transition in glioblastoma multiforme by targeting ZEB1 and ZEB2. Biochem Biophys Res Commun. 2015; 468(4):739-45. DOI: 10.1016/j.bbrc.2015.11.025. View

Wang Z, Zhang S, Siu T, Huang S . Glioblastoma multiforme formation and EMT: role of FoxM1 transcription factor. Curr Pharm Des. 2014; 21(10):1268-71. PMC: 4380124. DOI: 10.2174/1381612821666141211115949. View

Sayan A, Griffiths T, Pal R, Browne G, Ruddick A, Yagci T . SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci U S A. 2009; 106(35):14884-9. PMC: 2736415. DOI: 10.1073/pnas.0902042106. View

Xie R, Tang J, Zhu X, Jiang H . Silencing of hsa_circ_0004771 inhibits proliferation and induces apoptosis in breast cancer through activation of miR-653 by targeting ZEB2 signaling pathway. Biosci Rep. 2019; 39(5). PMC: 6522819. DOI: 10.1042/BSR20181919. View

Verschueren K, Remacle J, Collart C, Kraft H, Baker B, Tylzanowski P . SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5'-CACCT sequences in candidate target genes. J Biol Chem. 1999; 274(29):20489-98. DOI: 10.1074/jbc.274.29.20489. View

Qi S, Song Y, Peng Y, Wang H, Long H, Yu X . ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS One. 2012; 7(6):e38842. PMC: 3383704. DOI: 10.1371/journal.pone.0038842. View

Wu D, Zhang T, Liu Y, Deng S, Han R, Liu T . The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling. Cell Death Dis. 2019; 10(5):349. PMC: 6483988. DOI: 10.1038/s41419-019-1591-4. View

Zheng C, Guo K, Chen B, Wen Y, Xu Y . miR-214-5p inhibits human prostate cancer proliferation and migration through regulating CRMP5. Cancer Biomark. 2019; 26(2):193-202. DOI: 10.3233/CBM-190128. View

10.

Zhang X, Xu X, Ge G, Zang X, Shao M, Zou S . miR‑498 inhibits the growth and metastasis of liver cancer by targeting ZEB2. Oncol Rep. 2018; 41(3):1638-1648. PMC: 6365765. DOI: 10.3892/or.2018.6948. View

11.

Ko D, Kim S . Cooperation between ZEB2 and Sp1 promotes cancer cell survival and angiogenesis during metastasis through induction of survivin and VEGF. Oncotarget. 2018; 9(1):726-742. PMC: 5787504. DOI: 10.18632/oncotarget.23139. View

12.

Jin X, Nie E, Zhou X, Zeng A, Yu T, Zhi T . Fstl1 Promotes Glioma Growth Through the BMP4/Smad1/5/8 Signaling Pathway. Cell Physiol Biochem. 2017; 44(4):1616-1628. DOI: 10.1159/000485759. View

13.

Huo X, Huo B, Wang H, Zhang H, Ma Z, Yang M . Prognostic significance of the epithelial-mesenchymal transition factor zinc finger E-box-binding homeobox 2 in esophageal squamous cell carcinoma. Oncol Lett. 2017; 14(3):2683-2690. PMC: 5588115. DOI: 10.3892/ol.2017.6559. View

14.

Seystahl K, Tritschler I, Szabo E, Tabatabai G, Weller M . Differential regulation of TGF-β-induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma. Neuro Oncol. 2014; 17(2):254-65. PMC: 4288525. DOI: 10.1093/neuonc/nou218. View

15.

Batash R, Asna N, Schaffer P, Francis N, Schaffer M . Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review. Curr Med Chem. 2017; 24(27):3002-3009. DOI: 10.2174/0929867324666170516123206. View

16.

Zhao J, Zhang L, Guo X, Wang J, Zhou W, Liu M . miR-212/132 downregulates SMAD2 expression to suppress the G1/S phase transition of the cell cycle and the epithelial to mesenchymal transition in cervical cancer cells. IUBMB Life. 2015; 67(5):380-94. DOI: 10.1002/iub.1381. View

17.

Lim M, Xia Y, Bettegowda C, Weller M . Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018; 15(7):422-442. DOI: 10.1038/s41571-018-0003-5. View

18.

Li H, Wang H, Ren Z . MicroRNA-214-5p Inhibits the Invasion and Migration of Hepatocellular Carcinoma Cells by Targeting Wiskott-Aldrich Syndrome Like. Cell Physiol Biochem. 2018; 46(2):757-764. DOI: 10.1159/000488734. View

19.

Gao J, Zhu M, Zhu X . miRNA-215-5p suppresses the aggressiveness of breast cancer cells by targeting Sox9. FEBS Open Bio. 2019; 9(11):1957-1967. PMC: 6823282. DOI: 10.1002/2211-5463.12733. View

20.

Li J, Yuan J, Yuan X, Zhao J, Zhang Z, Weng L . MicroRNA-200b inhibits the growth and metastasis of glioma cells via targeting ZEB2. Int J Oncol. 2015; 48(2):541-50. DOI: 10.3892/ijo.2015.3267. View